David A. Mathison, M.D.; John J. Condemi, M.D., F.A.C.P.; Frank W. Lovejoy Jr., M.D.; John H. Vaughan, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Cromolyn sodium (disodium cromoglycate), an inhibitor of antigen-antibody-induced mediator release, has been shown to prevent acute asthma in allergic subjects when inhaled prior to challenge with inhalant allergens. It has been available for general physician use in Great Britain since 1968 and is undergoing clinical trials in several U. S. centers.
Cromolyn sodium has been administered (20 mg powder inhalation, four or more times daily) in open trial to 29 adults with perennial asthma who had been corticoid-dependent and who completed a 14-week double blind, double crossover trial comparing cromolyn sodium and placebo. Patients kept daily record of symptoms and
David A. Mathison, John J. Condemi, Frank W. Lovejoy, John H. Vaughan. Cromolyn Sodium Trial in Perennial Asthmatics.. Ann Intern Med. 1970;72:810–811. doi: 10.7326/0003-4819-72-5-810_4
Download citation file:
Published: Ann Intern Med. 1970;72(5):810-811.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use